首页> 外文OA文献 >Design, Development, Validation, and Use of Synthetic Nucleic Acid Controls for Diagnostic Purposes and Application to Cystic Fibrosis Testing
【2h】

Design, Development, Validation, and Use of Synthetic Nucleic Acid Controls for Diagnostic Purposes and Application to Cystic Fibrosis Testing

机译:设计,开发,验证和用于诊断目的的合成核酸控件的应用及其在囊性纤维化测试中的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We have designed, tested, and validated synthetic DNA molecules that may be used as reference standard controls in the simultaneous detection of mutations in one or more genes. These controls consist of a mixture of oligonucleotides (100 to 120 bases long) each designed for the detection of one or more disease-causing mutation(s), depending on the proximity of the mutations to one another. Each control molecule is identical to 80 to 100 bases that span the targeted mutations. In addition, each oligonucleotide is tagged at the 5′ and 3′ ends with distinct nucleic acid sequences that allow for the design of complementary primers for polymerase chain reaction amplification. We designed the tags to amplify control molecules comprising 32 CFTR mutations, including the American College of Medical Genetics minimum carrier screening panel of 23, with one pair of primers in a single tube. We tested the performance of these controls on many platforms including the Applied Biosystems/Celera oligonucleotide ligation assay and the Tm Bioscience Tag-It platforms. All 32 mutations were detected consistently. This simple methodology allows for maximum flexibility and rapid implementation. It has not escaped our notice that the design of these molecules makes possible the production of similar controls for virtually any mutation or sequence of interest.
机译:我们已经设计,测试和验证了合成DNA分子,这些分子可以用作同时检测一个或多个基因突变的参考标准对照。这些对照由寡核苷酸(长100至120个碱基)的混合物组成,每种寡核苷酸都设计用于检测一个或多个致病突变,具体取决于突变彼此之间的接近程度。每个对照分子与跨越目标突变的80至100个碱基相同。此外,每个寡核苷酸在5'和3'末端标记有不同的核酸序列,从而可以设计用于聚合​​酶链反应扩增的互补引物。我们设计了标签,以扩增包含32个CFTR突变的控制分子,其中包括美国医学遗传学学会最小载体筛选小组(23个),在单个试管中带有一对引物。我们在许多平台上测试了这些对照的性能,包括Applied Biosystems / Celera寡核苷酸连接测定法和Tm Bioscience Tag-It平台。一致地检测到所有32个突变。这种简单的方法可以实现最大的灵活性和快速的实施。我们没有注意到,这些分子的设计使得针对几乎任何目的突变或序列的类似对照的生产成为可能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号